Literature DB >> 16170749

Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease.

Raymund R Razonable1, Robert A Brown, Atul Humar, Emma Covington, Emma Alecock, Carlos V Paya.   

Abstract

The epidemiology of infections with 5 human herpesviruses (HHVs) (HHV-6, HHV-7, HHV-8, varicella zoster virus [VZV], and Epstein-Barr virus [EBV]) was investigated during the first year after solid organ transplantation in 263 patients who received oral ganciclovir or valganciclovir prophylaxis. HHV-6B DNAemia was uncommon, HHV-6A DNAemia was not observed, and HHV-7 DNAemia was prevalent. HHV-6 and HHV-7 DNAemia were not significantly associated with cytomegalovirus (CMV) disease, although a trend toward higher incidence of CMV disease was observed in HHV-6 DNAemic patients. VZV and HHV-8 DNAemia were not detected. EBV infection was common, although incidence of high-level EBV DNAemia was low, especially in patients who received valganciclovir prophylaxis. EBV-related posttransplant lymphoproliferative disease was not observed up to 12 months after transplantation. Compared with historic data, data from the present study suggest that antiviral prophylaxis may lower the incidence, prevalence, or level of DNAemia for infection with HHV-6, HHV-8, VZV, and EBV but not for infection with HHV-7.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170749     DOI: 10.1086/466529

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Management of cytomegalovirus infection in solid organ transplantation.

Authors:  Camille N Kotton
Journal:  Nat Rev Nephrol       Date:  2010-10-26       Impact factor: 28.314

2.  Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay.

Authors:  Kaoru Wada; Naomi Kubota; Yoshinori Ito; Hiroshi Yagasaki; Koji Kato; Tetsushi Yoshikawa; Yasuyuki Ono; Hisami Ando; Yasuhiro Fujimoto; Tetsuya Kiuchi; Seiji Kojima; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

Review 3.  Monitoring and managing viral infections in pediatric renal transplant recipients.

Authors:  Patrizia Comoli; Fabrizio Ginevri
Journal:  Pediatr Nephrol       Date:  2011-02-26       Impact factor: 3.714

4.  Impact of human herpes virus 6 in liver transplantation.

Authors:  Raymund R Razonable; Irmeli Lautenschlager
Journal:  World J Hepatol       Date:  2010-09-27

5.  Relationship between cytomegalovirus DNA load in epithelial lining fluid and plasma of lung transplant recipients and analysis of coinfection with Epstein-Barr virus and human herpesvirus 6 in the lung compartment.

Authors:  Claudia C Bauer; Peter Jaksch; Stephan W Aberle; Heinrich Haber; Gyoergy Lang; Walter Klepetko; Hanns Hofmann; Elisabeth Puchhammer-Stöckl
Journal:  J Clin Microbiol       Date:  2006-12-06       Impact factor: 5.948

6.  VZV encephalitis following successful treatment of CMV infection in a patient with kidney transplant.

Authors:  Shahzaib Nabi; Pushpinderdeep Kahlon; Mariella Goggins; Anita Patel
Journal:  BMJ Case Rep       Date:  2014-12-02

7.  Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients.

Authors:  S A Pergam; C W Forsberg; M J Boeckh; C Maynard; A P Limaye; A Wald; N L Smith; B A Young
Journal:  Transpl Infect Dis       Date:  2011-02       Impact factor: 2.228

Review 8.  Human herpesvirus 6 infections after liver transplantation.

Authors:  Rima Camille Abdel Massih; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

9.  Two strategies for prevention of cytomegalovirus infections after liver transplantation.

Authors:  Philipp Simon; Max Sasse; Sven Laudi; David Petroff; Michael Bartels; Udo X Kaisers; Sven Bercker
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 10.  Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.

Authors:  Joshua A Hill; Danielle M Zerr
Journal:  Curr Opin Virol       Date:  2014-10-04       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.